New insider activity at Irhythm Technologies ( (IRTC) ) has taken place on July 6, 2026.

Key executives at Irhythm Technologies have recently trimmed their holdings in the company. Chief Medical and Scientific Officer and EVP of Advanced Technologies, Minang Turakhia, sold 1,423 shares of Irhythm Technologies stock in a transaction valued at $177,462. In a separate move, EVP of Strategy & Corporate Development, Sean Clinton Freeman, disposed of 918 shares, generating sale proceeds of $114,483. These insider sales highlight notable activity among Irhythm’s senior leadership team.

Irhythm Technologies saw analyst price targets trimmed in the last day as Evercore ISI’s MedTech Q2 preview, while noting healthy procedure volumes and capital spending, led to a more measured outlook on the stock’s upside. The adjustment reflects cautious expectations about near‑term performance rather than any negative company‑specific event, with shares reacting to this tempered growth view.